Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 35 Days Payable is 69.21 as of Dec. 2025, which is 50% above its 10-year median of 46.11. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,893 Consumer Packaged Goods companies, Star Combo Pharma ranks better than 76.76% on this metric.
The historical rank and industry rank for Star Combo Pharma's Days Payable or its related term are showing as below:
ASX:S66'
s Days Payable Range Over the Past 10 Years
Min: 24.02 Med: 46.11 Max: 113.52
Current: 80.85
During the past 9 years, Star Combo Pharma's highest Days Payable was 113.52. The lowest was 24.02. And the median was 46.11.
ASX:S66's Days Payable is ranked better than 76.76% of 1893
companies
in the Consumer Packaged Goods industry
Industry Median: 43.93
vs ASX:S66: 80.85
Star Combo Pharma's Days Payable
increased
from Dec. 2024 (53.60) to Dec. 2025 (69.21).
It may suggest that Star Combo Pharmadelayed paying its suppliers.
The historical data trend for Star Combo Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Star Combo Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma Days Payable vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Star Combo Pharma's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Combo Pharma (ASX:S66) has a Days Payable of 69.21 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Star Combo Pharma and its competitors. This is 50% above median its historical median of 46.11. Over the past decade, Star Combo Pharma's Days Payable has ranged from 24.02 to 113.52. According to the industry distribution chart, Star Combo Pharma ranks #440 out of 1893 companies in the Consumer Packaged Goods industry, placing it in the top 23.2%.
Is Star Combo Pharma's Days Payable too high?
Star Combo Pharma's current Days Payable of 69.21 is 50% above median its 10-year median of 46.11. Over the past 10 years, this metric has ranged from a low of 24.02 to a high of 113.52. The Consumer Packaged Goods industry median Days Payable is 43.93. Star Combo Pharma's value of 69.21 is 57.5% above this industry median. Based on the distribution chart, Star Combo Pharma ranks #440 out of 1893 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Days Payable compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #440 out of 1893 companies for Days Payable. This places Star Combo Pharma in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 43.93. Star Combo Pharma's value of 69.21 is 57.5% above this benchmark. Historically, Star Combo Pharma's own Days Payable has ranged from 24.02 to 113.52 over the past decade. While the company's 10-year median is 46.11 vs. the industry median of 43.93, Star Combo Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Consumer Packaged Goods company?
The median Days Payable among Consumer Packaged Goods companies is 43.93, based on 1,893 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current Days Payable of 69.21 is 57.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median Days Payable is 43.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current Days Payable is 69.21, which is 50% above median its own 10-year median of 46.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current Days Payable is 69.21, which is 50% above median its 10-year median of 46.11 and 57.5% above the Consumer Packaged Goods industry median of 43.93. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Days Payable is 69.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued.
The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Days Payable: 69.21 (50% above median its 10-year median of 46.11)
GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
Industry Position: 57.5% above the Consumer Packaged Goods median (#440 of 1893)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score
Get the complete analysis for ASX:S66
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
